2017201620152014 | 2013


Axillary Node Management for Breast Cancer: Is Less More?

Axillary Node Management for Breast Cancer: Is Less More?

Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer

This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.

CTS5 Predicts Late Distant Recurrence in Hormone Receptor-positive Breast Cancer

CTS5 Predicts Late Distant Recurrence in Hormone Receptor-positive Breast Cancer

The CTS5 model is based on nodal status, tumor size, 3 categories of tumor grade, and age as a continuous variable.

Breast Cancer: Foregoing Axillary Dissection May Not Affect Long-term Survival

Breast Cancer: Foregoing Axillary Dissection May Not Affect Long-term Survival

At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.

Are Narrower Margins Safer in Breast-conserving Surgery?

Are Narrower Margins Safer in Breast-conserving Surgery?

Study findings indicate that margin widths of at least 2 mm are associated with reduced risk of ipsilateral breast failure compared with narrower but uninvolved margins.

Exemestane Improves DFS, but Not OS, vs Tamoxifen in Hormone Receptor-positive Breast Cancer

Exemestane Improves DFS, but Not OS, vs Tamoxifen in Hormone Receptor-positive Breast Cancer

Translating these findings into clinical practice will require careful conversations with patients to weigh toxicity and potential benefits for each individual.

Ovarian Function Suppression May Improve Outcomes in Hormone Receptor-positive Breast Cancer

Ovarian Function Suppression May Improve Outcomes in Hormone Receptor-positive Breast Cancer

Further follow-up should help to clarify the safety and benefits of OFS for late breast cancer OS.

COX-2 Inhibition With Celecoxib Does Not Improve Breast Cancer Outcomes

COX-2 Inhibition With Celecoxib Does Not Improve Breast Cancer Outcomes

Elevated COX2 levels are associated with breast cancer progression. COX2 is transcriptionally regulated and enhances the aromatase pathway, especially in estrogen receptor-positive tumors.

Lapatinib May Improve Event-free Survival in HER2+ Breast Cancer

Lapatinib May Improve Event-free Survival in HER2+ Breast Cancer

Patients with stage II to III HER2+ breast cancer underwent tumor biopsy and were then randomly assigned to receive paclitaxel plus trastuzumab alone or with lapatinib for 16 weeks before surgery.

Pathological Complete Response Predicts RFS and DRFS in High-risk Breast Cancer

Pathological Complete Response Predicts RFS and DRFS in High-risk Breast Cancer

The findings support the use of pCR as a primary endpoint for accelerated approval of new drugs when EFS is evaluated in the relevant patient population.

Adding Dual mTOR Inhibitor to Fulvestrant Therapy Does Not Improve PFS in Breast Cancer

Adding Dual mTOR Inhibitor to Fulvestrant Therapy Does Not Improve PFS in Breast Cancer

Patients were randomly assigned to receive fulvestrant, fulvestrant plus continuous daily vistusertib, fulvestrant plus intermittent vistusertib, or fulvestrant plus everolimus.

Does Long Non-coding RNA Increase Late-stage Relapse Risk for HR+ Breast Cancer?

Does Long Non-coding RNA Increase Late-stage Relapse Risk for HR+ Breast Cancer?

Long non-coding RNA bound to ESR-1 might contribute to late-stage HR+ breast cancer relapse, researchers reported.

Five-year Adjuvant Bisphosphonate Not Superior to 2-year Duration for Breast Cancer

Five-year Adjuvant Bisphosphonate Not Superior to 2-year Duration for Breast Cancer

Neither adapted DFS nor OS differed between the groups in multivariate analyses adjusted for patient and tumor variables and chemotherapy.

Genomic Instability Predicts Response to Trastuzumab Plus Lapatinib in ER+ Breast Cancer

Genomic Instability Predicts Response to Trastuzumab Plus Lapatinib in ER+ Breast Cancer

A total of 159 recurrent CNA regions were identified. ERBB2 amplification was associated with high pCR, but the association fell to insignificance after correcting for ERBB2 expression.

Does Radiotherapy Lead to An In Situ Breast Cancer Vaccine?

Does Radiotherapy Lead to An In Situ Breast Cancer Vaccine?

Preclinical studies suggest that radiotherapy's pro-immunogenic effects might improve the antitumor efficacy of immune checkpoint inhibition.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs